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The general separation between medical disciplines has, for decades, been a strange tradition. For example, neurologists and nephrologists have each had their defined patient groups, and many are barely interested, if at all, in the other discipline's research. Even within a specific field of basic science, such as physiology, neurophysiologists do not necessarily talk with other physiologists. Thus, the blood-brain barrier has been dividing more than two extracellular spaces. A credible exception may be found among clinical disciplines that focus on the patient as a whole, such as pediatrics. Children often present with complex syndromes that may be considered sporadic and without known genetic origins. Not having a specific diagnosis in such situations is frustrating for the patient, the family, and the physician. In addition, medical treatments for such patients are too often based on empirical measures rather than scientific grounds. Interestingly, some of these syndromes have turned out to be the result of single-gene disorders. In recent years, the diagnosis and treatment of some single-gene disorders have been substantially improved when the findings of basic and clinical research were combined. Major progress in molecular biology, molecular genetics, and cellular physiology has enabled development of both the tools and the mechanistic understanding to facilitate genetic identification of one disease after another, revealing the functional proteins involved in the observed pathophysiology. 1 In this issue of the Journal, Bockenhauer and colleagues 2 describe the molecular and functional features associated with a rare syndrome consisting of epilepsy, ataxia, sensorineural deafness, and salt-wasting renal tubulopathy and present data showing that the syndrome is due to mutations in a potassium-channel gene, KCNJ10. This syndrome, which they term the EAST syndrome, is accompanied by compensatory disturbances in ion and acid-base balance. The authors used single-nucleotide polymorphisms as genetic markers to map the disease locus in four symptomatic children from a single consanguineous family; sophisticated bioinformatics and data processing in the context of the whole pedigree led to the identification of KCNJ10 as the causal functional link to the syndrome.
The homozygous missense mutations in patients with the EAST syndrome interfere with a very basic physiologic process that occurs in every cell. The activity of the sodium-potassium pump Na + /K + -ATPase generates a concentration gradient for potassium. Normally, the positively charged potassium channels translate the potassium gradient into a negative membrane voltage. This voltage, or the respective potassium current, is then used to drive a variety of cell functions, such as attenuation of neuronal excitation or secondary active electrolyte and substrate transport. Given these functions, it is hardly surprising that any cell or organ system with functionally relevant expression of KCNJ10 and a mutation might contribute to the constellation of symptoms of patients with the EAST syndrome. Such cells include glial cells, intermediate cells of the stria vascularis in the inner ear, and renal epithelial cells in the distal nephron (Fig. 1) .
A closer look into the functional organization of renal epithelial transport in the thiazide-sensitive segment of the renal tubule directly reveals that a defect in basolateral potassium conductance (now established as occurring mainly through KCNJ10) must influence the transport of sodium and chloride as well as that of calcium and magnesium (Fig. 1) . This is the case in the EAST syndrome, in which renal loss of magnesium becomes evident while partial compensation for the loss of sodium chloride occurs at the expense of hypokalemia, metabolic alkalosis, and hypocalciuria. Similarly, inactivating mutations of the sodium-chloride cotransporter in this segment of the kidney tubule lead to hypocalciuria in the Gitelman syndrome. 1 A mouse model in which Kcnj10 was ablated, or knocked out, had already existed for several years, but the animals died very early in life. The lethal phenotype of these Kcnj10 knockout mice suggested a key role for the potassium channel in embryonic development, but it also made an integrative analysis of channel function almost impossible. Retrospectively, the findings in this model also suggested an important role for this gene in vital functions such as the maintenance of salt and water balance, as also observed, for example, in animal models of other conditions caused by abnormalities in other electrolyte transport channels, such as Bartter's syndrome 3 and pseudohypoaldosteronism. 4 From the perinatal period until weaning, animals (and humans) with such abnormalities are especially sensitive to the loss of salt and water.
In the brain, the KCNJ10 channel is located in astroglia. The central nervous system houses far more glial cells than neurons, and it has become clear that interactions between neurons and glia play an essential role in the proper functioning of the central nervous system. In the brain, KCNJ10 provides what is termed spatial buffering, 5 as both potassium and neurotransmitters must be removed from the small extracellular fluid space The cellular model of salt transport in the distal convoluted tubule indicates that expression of KCNJ10 enables recirculation of potassium, thus feeding the pump necessary for continuous transport of sodium at the expense of ATP consumption and providing the driving force for the transport of chloride, calcium, and magnesium. A defect in KCNJ10 indirectly affects the transport of sodium chloride through impairment of potassium recycling. Thiazide diuretics are frequently used to directly inhibit sodium chloride transport by targeting the sodium chloride cotransporter in the luminal membrane.
in the brain into the glia, thereby providing a stable environment for controlled neuronal excitability. If spatial buffering becomes lost, hyperexcitability and impaired function of neuronal networks would be expected, as is the case in the EAST syndrome.
At least two clinically relevant lessons may be derived from the study by Bockenhauer and colleagues. First, connections have yet to be made between thousands of genes in the human genome and many physiologic functions and diseases. The present example indicates that the signs and symptoms of renal tubular defects provide the opportunity to discover a variety of potential hereditary disorders involved in the function and regulation of ion channels, tight-junction proteins, transporters, and pumps, since clinical measurements may provide excellent phenotyping. In addition, the mutation that defines the EAST syndrome shows that it is clinically rewarding to look to the kidney, even if the primary symptoms of a disease originate in a completely different organ, such as the brain.
The next step in the study of the EAST syndrome may be the exploitation of the new functional understanding of KCNJ10 to optimize current treatment strategies or even to develop new ones, some of which might have relevance beyond this syndrome. The KCNJ10 gene is important in epilepsy, ataxia, the inner ear, and renal salt transport. Even the possibility of a link between KCNJ10 and hypertension does not seem implausible.
Many forms of epilepsy cannot be diagnosed by traditional means, since patients often have normal electroencephalograms, as seen in patients with the EAST syndrome. Building informative animal models with the use of KCNJ10 mutations might facilitate the development of diagnostic measures that are more precise and treatments that are more effective.
With the delineation of the EAST syndrome, KCNJ10, a gene that has been known for some time, has been unmasked as a key regulator of salt transport in the kidney and as an important player in brain function. The story of this research demonstrates how conducting a careful clinical study of patients with a rare disorder may provide an informative approach to diagnosis and treatment that is of benefit to patients, doctors, and progress in the medical sciences. 2 Dr. Bleich reports receiving grant support from Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.
